Welcome to the e-CCO Library!

OP16: Endoscopic and clinical outcomes of upadacitinib in patients with moderately to severely active Crohn's disease by number and type of prior biologics
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Peyrin-Biroulet, L.(1)*;Parkes, G.(2);Rodríguez, C.(3);Siffledeen, J.(4);Wright, J.(5);Broide, E.(6);Ford, S.(7);Lacerda, A.P.(7);Oomen, J.(7);Garrison, A.(7);Berg, S.(7);Rubin, D.T.(8);
Created: Friday, 14 July 2023, 10:43 AM
OP16: Endoscopic and clinical outcomes of upadacitinib in patients with moderately to severely active Crohn’s disease by number and type of prior biologics
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Laurent Peyrin-Biroulet
Created: Friday, 14 July 2023, 2:22 PM
OP16: The first virtual chromoendoscopy artificial intelligence system to detect endoscopic and histologic remission in Ulcerative Colitis
Year: 2022
Source: ECCO'22
Authors: Iacucci, M.(1);Cannatelli, R.(2);Parigi, T.L.(1,3);Buda, A.(4);Labarile, N.(5);Nardone, O.M.(6);Tontini, G.E.(7);Rimondi, A.(7);Bazarova, A.(8);Bhandari, P.(9);Bisschops, R.(10);De Hertogh, G.(10);Del Amor, R.(11);Ferraz, J.G.(12);Goetz, M.(13);Gui, X.(14);Hayee, B.(15);Kiesslich, R.(16);Lazarev, M.(17);Naranjo, V.(11);Panaccione, R.(12);Parra-Blanco, A.(18);Pastorelli, L.(19);Rath, T.(20);Røyset, E.S.(21);Vieth, M.(22);Villanacci, V.(23);Zardo, D.(24);Ghosh, S.(25);Grisan, E.(26,27);
Created: Friday, 11 February 2022, 3:52 PM
OP17 Protein intakes and risk of inflammatory bowel disease in the European Prospective Investigation into Cancer and Nutrition cohort (EPIC-IBD)
Year: 2020
Source:

ECCO'20 Vienna

Authors:

C. Dong1, Y. Mahamat-Saleh2, A. Racine3, P. Jantchou4, S. Chan6, A. Hart5, F. Carbonnel3, M.C. Boutron-Ruault2

Created: Thursday, 30 January 2020, 10:12 AM
OP17: A molecular measure of inflammation in IBD patients based on transcriptional profiles from 2495 intestinal biopsies
Year: 2019
Source: ECCO'19 Copenhagen
Authors: Mayte Suarez-Farinas
Created: Tuesday, 28 May 2019, 3:32 PM
Crohn’s disease, Ulcerative colitis, CRP and other serum biomarkers, Transcriptomics
Files: 1
OP17: A molecular measure of inflammation in IBD patients based on transcriptional profiles from 2495 intestinal biopsies
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

R. Huang1, H. Irizar2, R. Kosoy3, W-m. Song3, A. Dinarzo3, K. Hao3, J. Rogers4, A. Atreja4, M. Mahajan3, A. Stojmirovic5, J. Perrigoue5, C. Brodmerkel5, S. Plevy5, J. Friedman5, J-F. Colombel4, M. Dubinsky4, B. Sands4, E. Schadt3, A. Kasarskis3, B. Losic3, C. Argmann3, M. Suarez-Farinas1,3

Created: Friday, 22 February 2019, 9:41 AM
OP17: IBD ulcers are characterized by bioactive interleukin-1 and transcriptomic hallmarks of stromal cell state reprogramming
Year: 2024
Source: ECCO'24 Stockholm
Authors: Mitsialis, Vanessa
Created: Tuesday, 30 April 2024, 5:03 PM
OP17: Impact of phenotypic and genetic factors on Crohn’s Disease evolution in a cohort of 13,926 patients
Year: 2021
Source: ECCO'21 Virtual
Authors: Zhang, Q.(1);Fachal, L.(1);Shawky, R.(2);Parkes, M.(2,3,4);Anderson, C.(1);Raine, T.(1,4)
Created: Wednesday, 2 June 2021, 4:12 PM
OP17: Impact of phenotypic and genetic factors on Crohn’s Disease evolution in a cohort of 13,926 patients
Year: 2021
Source: ECCO'21 Virtual
Authors: Qian Zhang
Created: Friday, 1 October 2021, 12:41 PM
Background

Patients with Crohn’s disease (CD) can develop complications including stricturing and penetrating disease [1, 2]. Although reliable baseline predictors of disease progression are urgently needed to inform management strategies, few studies have comprehensively explored the phenotypic and genetic determinants of disease progression in a sufficiently powered cohort.

Methods

We used data from 13,926 patients with CD in the UK IBD BioResource to investigate the effects of clinical phenotypes and genetics on CD progression. Median follow-up was 10.6 years and total follow-up was 193,033 patient-years. We applied the Montreal classification system to define disease as B1 (inflammatory), B2 (stricturing) and B3 (penetrating). Patients with B2 or B3 disease (N = 5,185) were compared to patients with B1 disease (N = 8,471) in a multivariate model fitted with both phenotype data and a polygenic score that we developed. Associations with q-values (false discovery rate adjusted p-values) less than 0.05 were defined as statistically significant.

Results

CD progression occurred over time from diagnosis (Figure 1). Consistent with previous findings, we confirmed factors including smoking, disease location and perianal disease were associated with disease progression [3] (Table 1). The impact of a genetic influence on disease progression was confirmed and shown to be independent of genetic effects on disease location [4]. Early prescription of medications showed a protective effect on disease progression: Infliximab, adalimumab and thiopurines significantly reduced the chance of B2/B3 progression when prescribed within two years of diagnosis. Additionally, we observed a decreased progression to B2/B3 disease in patients diagnosed recently (between 2012-2020) compared to those diagnosed before 2012. This finding persisted after conditioning on exposure to biologics and correcting for follow-up time and interval to first thiopurine prescription, and thus may be indicative of other improvements in standards of care in recent years.

Conclusion

Using a large, well-characterised cohort we confirm the importance of disease location, smoking status and genetics on disease progression. We highlight the positive impact of early medication prescription on disease progression and discover an independent signal relating to potential improvements in the standard of care in CD over time. These results create the framework for reliable predictors of CD progression that may better guide future CD management strategies.

Reference:
1. Cosnes, J., et al., Inflamm Bowel Dis, 2002. 8(4): 244-50
2. Lo, B., et al.,J Crohns Colitis, 2018. 12(3): 265-272
3. Torres, J., et al., J Crohns Colitis, 2016. 10(12): 1385-1394
4. Cleynen, I., et al., Lancet, 2016. 387(10014): 156-67


OP17: Maintenance phase propensity score adjusted effectiveness and persistence at week-52 in biologic-naïve Ulcerative Colitis patients treated with vedolizumab or anti-TNF (VEDO IBD-study)
Year: 2022
Source: ECCO'22
Authors: Plachta-Danielzik, S.(1);di Giuseppe, R.(2);Bokemeyer, B.(3);Efken, P.(4);Mohl, W.(5);Krause, T.(6);Hoffstadt, M.(7);Ehehalt, R.(8);Trentmann, L.(9);Schweitzer, A.(10);Jessen, P.(11);Franzenburg, S.(1);Hartmann, P.(4);Schreiber, S.(12);
Created: Friday, 11 February 2022, 3:52 PM
OP17: Protein intakes and risk of Inflammatory Bowel Disease in the European Prospective Investigation into Cancer and Nutrition cohort (EPIC-IBD).
Year: 2020
Source: ECCO'20 Vienna
Authors: Catherine Dong
Created: Tuesday, 23 June 2020, 4:58 PM
Files: 1
OP17: Upadacitinib Improves Endoscopic Outcomes in Patients with Moderate to Severely Active Crohn's Disease Irrespective of Previous Failure to Respond to Biologics or Conventional Therapies
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Feagan, B.G.(1)*;Horst, S.(2);Dryden, G.(3);Lindsay, J.O.(4);Ferrante, M.(5);Dubenco, E.(6);Lacerda, A.P.(6);Ford, S.(6);Anyanwu, S.I.(6);Zhou, Q.(6);Liu, J.(6);Chen, M.(7);Schreiber, S.(8);
Created: Friday, 14 July 2023, 10:43 AM
OP18 Surgical prevention of anastomotic recurrence by excluding mesentery in Crohn’s disease: The SuPREMe-CD study
Year: 2020
Source:

ECCO'20 Vienna

Authors:

G. Luglio, A. Rispo, N. Imperatore, A. Amendola, F.P. Tropeano, R. Peltrini, F. Castiglione, G.D. De Palma, L. Bucci

Created: Thursday, 30 January 2020, 10:12 AM
OP18: Disease course of Crohn's disease during the first ten years following diagnosis in a prospective European population-based inception cohort – the Epi-IBD cohort
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Wewer, M.D.(1)*;Salupere, R.(2);Kievit, H.A.L.(3);Nielsen, K.R.(4);Midjord, J.(4);Domislovic, V.(5);Krznarić, Ž.(5);Pedersen, N.(6);Kjeldsen, J.(7);Eriksson, C.(8);Halfvarson, J.(8);Talbot, A.(9);Sebastian, S.(9);Goldis, A.(10);Misra, R.(11);Arebi, N.(11);Ilus, T.(12);Oksanen, P.(12,13);Neuman, A.(14);Andersen, V.(15,16,17);Skamnelos, A.(18);Katsanos, K.H.(18);Platon, V.(19);Turcan, S.(19);Borg, B.(20);Ellul, P.(20);Kupcinskas, J.(21);Kiudelis, G.(21);Yzet, C.(22);Fumery, M.(22);Kaimakliotis, I.P.(23);Lorenzon, G.(24);D'Inca, R.(24);Hernandez, V.(25,26);Fernandez, A.(27);Langholz, E.(28);Munkholm, P.(29);Burisch, J.(1);
Created: Friday, 14 July 2023, 10:43 AM
OP18: Efficacy and safety of filgotinib for the treatment of perianal fistulizing Crohn’s Disease: Results from the phase 2 DIVERGENCE 2 study
Year: 2022
Source: ECCO'22
Authors: Reinisch , W.(1);Colombel , J.F.(2);D’Haens , G.R.(3);Rimola , J.(4);DeHaas-Amatsaleh , A.(5);McKevitt , M.(6);Ren , X.(6);Serone , A.(6);Schwartz , D.A.(7);Gecse , K.B.(3);
Created: Friday, 11 February 2022, 3:52 PM
OP18: Proactive adalimumab trough measurements increase corticosteroid-free clinical remission in paediatric patients with Crohn’s disease: the paediatric Crohn’s disease adalimumab-level-based optimisation treatment (PAILOT) trial
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

A. Assa*1, M. Matar2, D. Turner3, E. Broide4, B. Weiss5, O. Ledder6, A. Guz Mark2, F. Rinawi2, S. Cohen7, C. Topf Olivestone8, R. Shaoul9, B. Yerushalmi10, R. Shamir2

Created: Friday, 22 February 2019, 9:41 AM